Targeted Genetics’ Legacy: No Cures, But a Generation of Seattle Biotechies
Luke Timmerman8/25/09Comments (5)Follow @ldtimmerman
(Page 2 of 2)
—Justine Dell’Aringa, associate scientist, Amgen
—Ben Dutzar, scientist, Alder Biopharmaceuticals
—Eric Eith, technical operations, ZymoGenetics
—Paul Engelbrecht, quality control supervisor, Dendreon
—Andrew Feldhaus, scientist, ZymoGenetics
—Lindsay Felker, analytical biochemist, CMC-Icos
—Heather Franklin, senior vice president of business development, ZymoGenetics
—Victor Fung, executive director at Amgen in Seattle, manufacturing expert
—Deborah Garrard, senior project manager, Seattle Genetics
—Alison Grady, quality assurance associate, Seattle Genetics
—Simon Grainger, Seattle account manager, VWR International
—Kari Hale, associate scientist, Amgen
—Paul Hara, senior director of program management, MDS Pharma Services
—Pierrot Harvie, scientist, MDRNA
—Vaughn Himes, executive vice president, technical operations, Seattle Genetics
—Damon Jacobson, clinical research associate, Seattle Children’s Hospital
—James Johnson, chief financial officer, ZymoGenetics
—Lori A. Jones, cellular immunologist, Seattle Cancer Care Alliance
—Eric Keeler, sales and business development, EMD Chemicals
—Edward Kelly, assistant professor, University of Washington
—Chris Kuehn, senior research associate, Trubion Pharmaceuticals
—Dan LaFoe, head of manufacturing, Catch, Inc.
—Dara Lockert, owner, Lockert Project Solutions
—Kurt Lustig, scientist at VLST
—Carmel Lynch, scientist at Seattle Genetics
—Linda MacDonald (formerly Rogers), scientist, NanoString Technologies
—Brad Miller, quality control supervisor, Bio-Rad Laboratories
—Christine Moore, quality assurance associate, Seattle Cancer Care Alliance
—Keith Munson, senior CMC project manager at CMC ICOS Biologics
—Peter Olagunju, compliance manager, ZymoGenetics
—Jason Orthel, pharmacist, Seattle Children’s Hospital
—Bob Overell, president of PhaseRx
—Ralph Paul, Cerep
—Aaron Posey, scientist at VLST
—Pauline Quigley, program manager, University of Washington Center for Systems and Translational Research on Infectious Disease (STRIDE) [Added: 10 am, 3/24/10]
—Tina Quinton, patent attorney, Christensen O’Connor Johnson Kindness
—Tom Reynolds, chief medical officer, Seattle Genetics
—Aimee Roy, quality assurance supervisor, Dendreon
—Tsering Sangmo, senior lab technologist
—David Schubert, president of Accelerator
—Todd Simpson, chief financial officer, Seattle Genetics
—Stephanie Seiler, founder of Gemini BioProjects, contract communications
—Chuck Smith, senior director of quality, Seattle Genetics
—Tony Stepan, field applications specialist, Promega
—Ryan Takeya, biotech manufacturing consultant
—Joe Weil, senior scientist, Trubion Pharmceuticals
—Perry Wilkins, account manager for Invitrogen
—Linda Wilson, scientist, Amgen
—Eden Zasloff, clinical site manager, PrexEra/Quintiles
—Leah Zielinski Yount, quality assurance at Seattle Biomedical Research Institute
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
Tony
8/25/09 7:40 pm
Luke,
Thanks for touching upon this undeniable and rarely mentioned aspect of the Targeted Genetics story. Throughout its 17 year roller coaster ride TGC has not only been a major career stepping stone for many, but also a source of enduring friendships (as well as a number number of marriages;). Although the company’s contribution to the bruised local biotech economy is sadly waning its DNA is very much woven in the current landscape as evidenced by the following Linked0n list of former TGC employees that are still active and contributing in the local scene:
Tara Allen, Clinical Research Associate at Dendreon
Deborah Garrard, Senior Project Manager at Seattle Genetics
Edward Kelly, Research Assistant Professor at University of Washington
Daryn Debelak, Seattle Account Manager Invitrogen Life Tech
Perry Wilkins, Seattle Account Manager Invirtogen Life Tech
Tsering Sangmo, Sr. Lab Tech, Seattle
Peter Olagunju, Compliance Manager, ZymoGenetics Inc.
Ian Aranha, Associate Scientist – Bayer
HealthCare Pharmaceuticals – Seattle
Alison Grady, QC Supervisor/Project Manager
Simon Grainger, Seattle Account Manager at VWR International
Devon DeHaas, Seattle Account Manager at VWR International
Kari Hale, Associate Scientist at Amgen
Pierrot Harvie, Research Scientist at MDRNA
Haim Burstein, Scientist
Aimee Roy, QA Supervisor at Dendreon Corporation
Ave-teel Connie, Lab Support, Manager at ICOS Corporation
Damon Jacobson, Clinical Research Associate in Hematology/Oncology
Tony Stepan – Seattle Applications Specialist at Promega
Justine Dell’Aringa- Associate Scientist at Amgen
Eric Eith, ZymoGenetics
Christine Moore,QA Associate – Seattle Cancer Care Alliance
Paul Engelbrecht,Quality Control Supervisor Dendreon
Keith Munson,Senior CMC Project Manager at CMC ICOS Biologics
Charles Wallsmith, Biotech IT Consultant
Gina Nichols, Staff Scientist
Leah Zielinski Yount , QA Associate at Seattle Biomedical Research Institute
Rema Assaf, Senior Project Manager at Seattle Genetics
Brad Miller – QC Supervisor at Bio-Rad Laboratories
Paul Hara, Senior Director, Program Management at MDS Pharma Services
Ben Dutzar , Research Scientist at Alder Biopharmaceuticals
Eric Keeler , Sales and Business Development
Alison Grady, QC Supervisor/Project Manager
Holly Craven, QC Analyst ZymoGenetics
Tina Quinton, Patent Attorney at Christensen O’Connor Johnson Kindness
Lara Stepan, Scientist Amgen
Lawrence Evans, Scientist Amgen
Lisa
Linda Wilson, Scientist Amgen
Eden Zasloff, Clinical Research Associate
Lori Jones, Cellular Immunologist Seattle Cancer Care Alliance
Teresa Johnston Manager Quality Control at CMC ICOS Corporation
Chuck Smith, Sr. Director of Quality at Seattle Genetics
Kevin Anderson, Principal Scientist at Seattle Genetics
Susan Bell, Research Associate at MDRNA Inc
Andrew Feldhaus, Principal Scientist at ZymoGenetics
Todd Allen, Technical Operations at ZymoGenetics
Emily Bradeen-Duncan, Manufacturing QA Associate II at Seattle Genetics
Jason Orthel, Pharmacist Seattle
Luke Timmerman
8/25/09 8:20 pm
Tony—thanks very much for this very informative comment. I actually thought about using LinkedIn for this story, but hesitated because I’ve noticed some people letting their profiles get out of date. If anybody here on the list has a new title or employer, you can update it here in the comment stream.
Luke
Justine Dell'Aringa
9/3/09 3:01 pm
What a pleasant surprise it is to come across this article, indeed TGC was an excellent training ground and inspirational place to work. I always felt fortunate that I was hired at TGC right out of collage. I was trained by top notch scientists and surround by innovation and wonderful people excited about the work they were doing, what a great first introduction to the biotech industry! …and not doubt, Stewart Parker is a wonderful leader and an excellent example of a talented and successful woman in science. It’s nice to think of all that hard work infiltrating and energizing the local biotech industry. I most definitely have applied the skills I acquired while working at TGC at other companies and still am today. Thanks for pointing out the positive, and thanks to everyone who made TGC such a great place to work.
Kari Hale
9/4/09 1:41 pm
Thank you for acknowledging this wonderful biotech as I am one that benefited from its existence. TGC was a mentoring ground that provided many just out of college a place to understand the industry but still base decisions and projects on research not just the bottom line. The management led by Stewart and Barrie surrounded us with enthusiasm and support if you were cleaning the glassware or leading pre-clinical trials your input was essential. A disease might not have been cured(YET-technology lives on) yet TGC pushed the science bar and produced leading edge biotech-ers. THANK YOU TGC & I miss happy hour intercom calls!